SCIENTIFIC HUB

Follow the evidence.

20.648 articles found

Open access

Author Correction: Time-to-event analysis mitigates the impact of symptomatic therapy on therapeutic benefit in Parkinson's disease trials.

Pagano G, Trundell D, Simuni T, Pavese N, Marek K, Postuma RB, Shariati N, Monnet A, Moore E, Davies EW, Svoboda H, Pross N, Bonni A, Nikolcheva T, PASADENA Investigators, Prasinezumab Study Group.

NPJ Parkinsons Dis · 2025-08-13

DOI: 10.1038/s41531-025-01103-yPMID: 40804248

A bibliographic record traceable to Europe PMC. Türkçe başlık: makine çevirisi, editoryal kontrol bekliyor.
Source record

Corrigendum to "Shared pathogenic mechanisms of Parkinson's disease and ulcerative colitis: α7 nicotinic acetylcholine receptor as a potential therapeutic target" [Int. J. Biol. Macromol. 2025 Jul 1; 319(Pt 4):145701].

Li Y, Gu Y, Li J, Liu F, Chen H, Hou H, Hu Q.

Int J Biol Macromol · 2025-08-13

DOI: 10.1016/j.ijbiomac.2025.146651PMID: 40803985

A bibliographic record traceable to Europe PMC. Türkçe başlık: makine çevirisi, editoryal kontrol bekliyor.
Source record

Clinical insights into catechin-based nanomedicine: a review of therapeutic potential in neurodegenerative diseases.

Al Amin M, Zehravi M, Sweilam SH, Shanmugarajan TS, Arjun UVNV, Nagaiyan MB, Reddy SM, Subash V, Swarnalatha KM, Pazhanikumar A, Mart J, Prasad PD, Khan MI, Ahmad I, Emran TB.

3 Biotech · 2025-08-13

DOI: 10.1007/s13205-025-04470-8PMID: 40822422

A bibliographic record traceable to Europe PMC. Türkçe başlık: makine çevirisi, editoryal kontrol bekliyor.

Records come from scientific sources. Bibliographic counts do not represent completed translations or editorial approvals.

Filters

Filters

Clear
Publication year
Research area
Author
Journal
Publication type
Source & language
Open accessAccess does not establish reuse rights.